Skip to main content
. 2021 Dec 14;12:707542. doi: 10.3389/fimmu.2021.707542

Figure 3.

Figure 3

Schematic of NK cell sources and CAR-NK cell/immune therapy workflow: NK cells harvested from multiple sources, followed by NK-cell activation by IL-2 and subsequent transduction with a construct encoding CAR. Next, these reprogrammed CAR-NK cells are expanded ex-vivo and passed through strict quality control testing before cryopreservation and subsequent validation and approval for final clinical administration.